Merck & Co.
pharmaceutical company
Best podcasts with Merck & Co.
Ranked by the Snipd community
Oct 24, 2023 • 28min
Ep. 200 - Merck-Daiichi, Roche-Roivant, Base Editors
Merck & Co. in-licenses three Antibody Drug Conjugates (ADCs) from Daiichi Sankyo in a $4 billion deal. The podcast also discusses Roche's $7.1 billion deal for Roivant Sciences' Telavant subsidiary and the expanding therapeutic potential of base editors in gene editing.
